News

Releasing Medical Records to Patients: Fact vs. Fiction

This is a test embeding of a mobile scale onto a liferay page.

When counseling trauma victims and patients with PTSD, do you ask them to retell the trauma or do you think this prolongs it?

In a childhood obesity article, the JAMA authors suggest "involvement of state protective services . . . including placement into foster care in carefully selected situations" as an alternative to treatment at newly established pediatric surgical weight loss programs. Do you agree?

Psychiatric Times has invited the editors of h-madness, a blog that follows the history of psychiatry, to share a monthly guest blog with our readers. You can read more about the history of psychiatry on their blog.

It’s hard to believe that it’s been two years since I saw my first patient in my very own office.

There are a couple of facets of human nature that have a big impact on how people perceive EHRs and what they do, or don't do, with them.

The entire field of psychiatric epidemiology has a systematic bias that leads it to misleadingly report what are highly inflated rates of psychiatric disorder.

When Leo Alexander, the psychiatrist who served as advisor at the Nuremberg doctors’ trial, helped draft the articles of the Nuremberg code, his attention was drawn to two earlier episodes in German medical history.

The doctor-patient relationship is built upon a foundation of trust. What do we do when a patient compromises or starts to bend the trust?

The good news is that several resources provide guidance regarding market compensation. Here’s how that information will help you.

A newly appointed DSM-5 scientific review group is meant to “review the reviews”-but it is working in secret and so far appears to be a remarkably porous filter . . .DSM-5 has shown no capacity to self-monitor and self-correct. An outside review is sorely needed-and fortunately a ready mechanism is in place.

Is all the time, effort and money (not to mention the stress) really going to positively influence patient well-being?

A comprehensive treatment plan is a systematic, thorough, painstaking therapeutic program that takes time for implementation and results

I just read a blog by Dr Dayle Jones that could have an important influence in the endgame effort to save DSM-5 from itself.

This poll is inspired by a recent post in Diagnostic Imaging and the Great American Physician survey by our sister publication, Physicians Practice.

So, how does a practice increase their percentage of collection? Two words: use technology.

Although his plays are suffused with dynastic and generational issues, Shakespeare hardly wrote anything about grandparents per se.

I believe that holistically understanding health policy - as seen through both “donkey” and “elephant” eyes - makes me a better clinician.

Attempting to write an article about 9/11 is fraught with peril from the outset. What can be said that is not repetitious? Then there is the ever present risk of offending those whose lives were forever changed in an overawing, tragic manner.

Psychiatric symptoms are fairly ubiquitous in the general population- most normal people have at least one, many have a few. When present in isolation, a single symptom (or even a few) does not a psychiatric disorder make. Two additional conditions must also be met before a symptom can be considered to be part of a mental disorder.

their silver bodies glinting in the twilight . . . like shards of broken glass, wing-tip lights . . . flashing like towers on tall buildings

The proposed Conditions of Participation (CoPs) from Medicare for community mental health centers (CMHCs) could expand the role and responsibilities of psychiatrists both in and beyond Medicare facilities.

Addressing the Underlying Causes of Treatment Resistance

As GOP candidates carve out their healthcare platforms, physicians should perk up their ears and prepare to compare.

Cognitive-behavioral therapy, interpersonal psychotherapy, or antidepressants can be effective treatments for major depression-despite their minimal separation from placebo/control therapies in clinical trials. This article argues that their specific efficacy has not been established.

The Alzheimer’s Association announced in July that the FDA had accepted its recommendations to modify exclusion and monitoring criteria for clinical trials of agents that affect β-amyloid protein in the brain.

In my view, Dr Angell’s assertions reflect both a serious misunderstanding of psychiatric diagnosis, and-equally important-a failure to address the core philosophical issues involved in her use of the terms “subjective,” “objective,” “behaviors,” and “signs.”